{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:03:49Z","timestamp":1772471029169,"version":"3.50.1"},"reference-count":41,"publisher":"Walter de Gruyter GmbH","issue":"3-4","funder":[{"DOI":"10.13039\/501100008770","name":"Anadolu \u00c3\u0153niversitesi","doi-asserted-by":"publisher","award":["Project Numbers: 2204S034 and 2209S149), Eskisehir"],"award-info":[{"award-number":["Project Numbers: 2204S034 and 2209S149), Eskisehir"]}],"id":[{"id":"10.13039\/501100008770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. There are a number of other extrapyramidal conditions that can make the diagnosis challenging. Unlike other neurodegenerative diseases, idiopathic PD has effective treatments that mitigate symptoms. Inspired by the existing findings related to the hypothesis such as activated monoamine oxidase (MAO) enzyme, we have developed a series of new molecules that serve as inhibitors for MAO-B enzyme. In this investigation, a range of nitrogen-containing heterocyclic as thiosemicarbazone derivatives, are explored to showcase their functionality as inhibitors of MAO-B enzymes. This study characterizes and validates their potential as new agents for addressing PD. The produced compounds were assessed for their biological activity and cytotoxicity using nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS) spectroscopy. The biological activity and cytotoxicity studies were performed for the synthesized molecules as\n                    <jats:italic>h<\/jats:italic>\n                    MAO-B inhibitors. Among the designed compounds,\n                    <jats:bold>3g<\/jats:bold>\n                    demonstrated the best MAO-B inhibitory activity and optimal docking poses and stability in the molecular dynamic\u2019s studies. Based on the data obtained, molecule\n                    <jats:bold>3g<\/jats:bold>\n                    was a candidate for further investigations. Theoretical pharmacokinetic and drug ability studies showed favorable properties to the candidate compound\n                    <jats:bold>3g<\/jats:bold>\n                    among other synthesized molecules.\n                  <\/jats:p>","DOI":"10.1515\/znc-2025-0107","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T12:01:58Z","timestamp":1755172918000},"page":"253-265","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, investigation, and biological activity assessments of\n                    <i>n<\/i>\n                    -allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents"],"prefix":"10.1515","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-8067","authenticated-orcid":false,"given":"Sazan","family":"Haji Ali","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry , 125618 College of Pharmacy, Hawler Medical University , Erbil 44000 , Iraq"},{"name":"Central Research Laboratory, Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-436X","authenticated-orcid":false,"given":"Derya","family":"Osmaniye","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"},{"name":"Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-6266","authenticated-orcid":false,"given":"Beg\u00fcm Nurpelin","family":"Sa\u011fl\u0131k \u00d6zkan","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"},{"name":"Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Levent","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"},{"name":"Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"\u00d6zkay","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"},{"name":"Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer As\u0131m","family":"Kaplanc\u0131kl\u0131","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry , Faculty of Pharmacy, Anadolu University , Eski\u015fehir 26470 , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"2026030216130880215_j_znc-2025-0107_ref_001","doi-asserted-by":"crossref","unstructured":"Prajjwal, P, Flores Sanga, HS, Acharya, K, Tango, T, John, J, Rodriguez, RSC, et al.. Parkinson\u2019s disease updates: addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. Ann Med Surg 2023;85:4887\u2013902. https:\/\/doi.org\/10.1097\/ms9.0000000000001142.","DOI":"10.1097\/MS9.0000000000001142"},{"key":"2026030216130880215_j_znc-2025-0107_ref_002","unstructured":"Parkinson\u2019s Disease: Challenges. Progress, and promise | National Institute of Neurological Disorders and Stroke. [Internet]. Available from: https:\/\/www.ninds.nih.gov\/current-research\/focus-disorders\/parkinsons-disease-research\/parkinsons-disease-challenges-progress-and-promise [cited 19 Aug 2024]."},{"key":"2026030216130880215_j_znc-2025-0107_ref_003","doi-asserted-by":"crossref","unstructured":"Tanner, CM, Goldman, SM. Epidemiology of Parkinson\u2019s disease. Neurol Clin 1996;14:317\u201335. https:\/\/doi.org\/10.1016\/s0733-8619(05)70259-0.","DOI":"10.1016\/S0733-8619(05)70259-0"},{"key":"2026030216130880215_j_znc-2025-0107_ref_004","doi-asserted-by":"crossref","unstructured":"Nussbaum, RL, Ellis, CE. Alzheimer\u2019s disease and Parkinson\u2019s disease. N\u00a0Engl J Med 2003;348:1356\u201364. https:\/\/doi.org\/10.1056\/nejm2003ra020003.","DOI":"10.1056\/NEJM2003ra020003"},{"key":"2026030216130880215_j_znc-2025-0107_ref_005","unstructured":"Kouli, A, Torsney, KM, Kuan, WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker, TB, Greenland, JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects [Internet]. Brisbane, AU: Codon Publications; 2018."},{"key":"2026030216130880215_j_znc-2025-0107_ref_006","doi-asserted-by":"crossref","unstructured":"Kalia, LV, Lang, AE. Parkinson\u2019s disease. Lancet 2015;386:896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3.","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"2026030216130880215_j_znc-2025-0107_ref_007","doi-asserted-by":"crossref","unstructured":"Weerasinghe-Mudiyanselage, PDE, Kang, S, Kim, JS, Moon, C. Therapeutic approaches to non-motor symptoms of Parkinson\u2019s disease: a current update on preclinical evidence. Curr Neuropharmacol 2023;21:560\u201377. https:\/\/doi.org\/10.2174\/1570159x20666221005090126.","DOI":"10.2174\/1570159X20666221005090126"},{"key":"2026030216130880215_j_znc-2025-0107_ref_008","doi-asserted-by":"crossref","unstructured":"Hussein, A, Guevara, CA, Valle, PD, Gupta, S, Benson, DL, Huntley, GW. Non-motor symptoms of Parkinson\u2019s disease: the neurobiology of early psychiatric and cognitive dysfunction. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 2023;29:97\u2013116.","DOI":"10.1177\/10738584211011979"},{"key":"2026030216130880215_j_znc-2025-0107_ref_009","doi-asserted-by":"crossref","unstructured":"Parkinson, J. An essay on the shaking palsy. 1817. J\u00a0Neuropsychiatry Clin Neurosci 2002;14:223\u201336. discussion 222. https:\/\/doi.org\/10.1176\/appi.neuropsych.14.2.223.","DOI":"10.1176\/jnp.14.2.223"},{"key":"2026030216130880215_j_znc-2025-0107_ref_010","doi-asserted-by":"crossref","unstructured":"Cheng, HC, Ulane, CM, Burke, RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715\u201325. https:\/\/doi.org\/10.1002\/ana.21995.","DOI":"10.1002\/ana.21995"},{"key":"2026030216130880215_j_znc-2025-0107_ref_011","doi-asserted-by":"crossref","unstructured":"Hayes, MT. Parkinson\u2019s disease and parkinsonism. Am J Med 2019;132:802\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.001.","DOI":"10.1016\/j.amjmed.2019.03.001"},{"key":"2026030216130880215_j_znc-2025-0107_ref_012","doi-asserted-by":"crossref","unstructured":"Tan, YY, Jenner, P, Chen, SD. Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future. J\u00a0Park Dis:2022:12:477\u201393. https:\/\/doi.org\/10.3233\/jpd-212976.","DOI":"10.3233\/JPD-212976"},{"key":"2026030216130880215_j_znc-2025-0107_ref_013","doi-asserted-by":"crossref","unstructured":"Simon, DK, Tanner, CM, Brundin, P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 2020;36:1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002.","DOI":"10.1016\/j.cger.2019.08.002"},{"key":"2026030216130880215_j_znc-2025-0107_ref_014","doi-asserted-by":"crossref","unstructured":"Titova, N, Chaudhuri, KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust 2018;208:404\u20139. https:\/\/doi.org\/10.5694\/mja17.00993.","DOI":"10.5694\/mja17.00993"},{"key":"2026030216130880215_j_znc-2025-0107_ref_015","doi-asserted-by":"crossref","unstructured":"Yi, C, Liu, X, Chen, K, Liang, H, Jin, C. Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson\u2019s disease. Eur J Med Chem 2023;252:115308. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115308.","DOI":"10.1016\/j.ejmech.2023.115308"},{"key":"2026030216130880215_j_znc-2025-0107_ref_016","doi-asserted-by":"crossref","unstructured":"Youdim, MBH, Bakhle, YS. Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 2006;147:S287\u201396. https:\/\/doi.org\/10.1038\/sj.bjp.0706464.","DOI":"10.1038\/sj.bjp.0706464"},{"key":"2026030216130880215_j_znc-2025-0107_ref_017","doi-asserted-by":"crossref","unstructured":"Tripathi, RKP, Sasi, VM, Gupta, SK, Krishnamurthy, S, Ayyannan, SR. Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site. J\u00a0Enzym Inhib Med Chem 2018;33:37\u201357. https:\/\/doi.org\/10.1080\/14756366.2017.1389920.","DOI":"10.1080\/14756366.2017.1389920"},{"key":"2026030216130880215_j_znc-2025-0107_ref_018","doi-asserted-by":"crossref","unstructured":"de la Fuente-Fern\u00e1ndez, R, Sossi, V, Huang, Z, Furtado, S, Lu, JQ, Calne, DB, et al.. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain 2004;127:2747\u201354. https:\/\/doi.org\/10.1093\/brain\/awh290.","DOI":"10.1093\/brain\/awh290"},{"key":"2026030216130880215_j_znc-2025-0107_ref_019","doi-asserted-by":"crossref","unstructured":"Riederer, P, M\u00fcller, T. Monoamine oxidase-B inhibitors in the treatment of Parkinson\u2019s disease: clinical\u2013pharmacological aspects. J\u00a0Neural Transm 2018;125:1751\u20137. https:\/\/doi.org\/10.1007\/s00702-018-1876-2.","DOI":"10.1007\/s00702-018-1876-2"},{"key":"2026030216130880215_j_znc-2025-0107_ref_020","doi-asserted-by":"crossref","unstructured":"Sz\u00f6k\u0151, \u00c9, T\u00e1bi, T, Riederer, P, V\u00e9csei, L, Magyar, K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J\u00a0Neural Transm 2018;125:1735\u201349. https:\/\/doi.org\/10.1007\/s00702-018-1853-9.","DOI":"10.1007\/s00702-018-1853-9"},{"key":"2026030216130880215_j_znc-2025-0107_ref_021","doi-asserted-by":"crossref","unstructured":"Son, SY, Ma, J, Kondou, Y, Yoshimura, M, Yamashita, E, Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors. Proc Natl Acad Sci U S A. 2008;105:5739\u201344. https:\/\/doi.org\/10.1073\/pnas.0710626105.","DOI":"10.1073\/pnas.0710626105"},{"key":"2026030216130880215_j_znc-2025-0107_ref_022","doi-asserted-by":"crossref","unstructured":"Medvedev, AE, Ivanov, AS, Veselovsky, AV, Skvortsov, VS, Archakov, AI. QSAR analysis of indole analogues as monoamine oxidase inhibitors. J\u00a0Chem Inf Comput Sci 1996;36:664\u201371. https:\/\/doi.org\/10.1021\/ci950126t.","DOI":"10.1021\/ci950126t"},{"key":"2026030216130880215_j_znc-2025-0107_ref_023","doi-asserted-by":"crossref","unstructured":"Seidl, SE, Potashkin, JA. The promise of neuroprotective agents in Parkinson\u2019s disease. Front Neurol 2011;2:68. https:\/\/doi.org\/10.3389\/fneur.2011.00068.","DOI":"10.3389\/fneur.2011.00068"},{"key":"2026030216130880215_j_znc-2025-0107_ref_024","doi-asserted-by":"crossref","unstructured":"Bainbridge, JL, Page, RL, Ruscin, JM. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Neurol Clin 2008;26:S85\u201396. vi. https:\/\/doi.org\/10.1016\/j.ncl.2008.05.002.","DOI":"10.1016\/j.ncl.2008.05.002"},{"key":"2026030216130880215_j_znc-2025-0107_ref_025","doi-asserted-by":"crossref","unstructured":"Osmaniye, D, Kurban, B, Sa\u011fl\u0131k, BN, Levent, S, \u00d6zkay, Y, Kaplanc\u0131kl\u0131, ZA. Novel thiosemicarbazone derivatives: in\u00a0vitro and in\u00a0silico evaluation as potential MAO-B inhibitors. Molecules 2021;26:6640. https:\/\/doi.org\/10.3390\/molecules26216640.","DOI":"10.3390\/molecules26216640"},{"key":"2026030216130880215_j_znc-2025-0107_ref_026","doi-asserted-by":"crossref","unstructured":"Can, N\u00d6, Osmaniye, D, Levent, S, Sa\u011fl\u0131k, BN, \u0130nci, B, Ilg\u0131n, S, et al.. Synthesis of new hydrazone derivatives for MAO enzymes inhibitory activity. Mol J Synth Chem Nat Prod Chem. 2017;22:1381. https:\/\/doi.org\/10.3390\/molecules22081381.","DOI":"10.3390\/molecules22081381"},{"key":"2026030216130880215_j_znc-2025-0107_ref_027","doi-asserted-by":"crossref","unstructured":"Can, N\u00d6, Osmaniye, D, Levent, S, Sa\u011fl\u0131k, BN, Korkut, B, Atl\u0131, \u00d6, et al.. Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors. Eur J Med Chem 2018;144:68\u201381. https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.013.","DOI":"10.1016\/j.ejmech.2017.12.013"},{"key":"2026030216130880215_j_znc-2025-0107_ref_028","doi-asserted-by":"crossref","unstructured":"Sa\u011fl\u0131k, BN, Kaya \u00c7avu\u015fo\u011flu, B, Osmaniye, D, Levent, S, Acar \u00c7evik, U, Ilg\u0131n, S, et al.. In vitro and in\u00a0silico evaluation of new thiazole compounds as monoamine oxidase inhibitors. Bioorg Chem 2019;85:97\u2013108. https:\/\/doi.org\/10.1016\/j.bioorg.2018.12.019.","DOI":"10.1016\/j.bioorg.2018.12.019"},{"key":"2026030216130880215_j_znc-2025-0107_ref_029","doi-asserted-by":"crossref","unstructured":"Tok, F, Ko\u00e7yi\u011fit-Kaymak\u00e7\u0131o\u011flu, B, Sa\u011fl\u0131k, BN, Levent, S, \u00d6zkay, Y, Kaplanc\u0131kl\u0131, ZA. Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. Bioorg Chem 2019;84:41\u201350.","DOI":"10.1016\/j.bioorg.2018.11.016"},{"key":"2026030216130880215_j_znc-2025-0107_ref_030","doi-asserted-by":"crossref","unstructured":"Tok, F, Sa\u011fl\u0131k, BN, \u00d6zkay, Y, Ilg\u0131n, S, Kaplanc\u0131kl\u0131, ZA, Ko\u00e7yi\u011fit-Kaymak\u00e7\u0131o\u011flu, B. Synthesis of new hydrazone derivatives and evaluation of their monoamine oxidase inhibitory activity. Bioorg Chem 2021;114:105038. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105038.","DOI":"10.1016\/j.bioorg.2021.105038"},{"key":"2026030216130880215_j_znc-2025-0107_ref_031","doi-asserted-by":"crossref","unstructured":"Sa\u011fl\u0131k, BN, Ilg\u0131n, S, \u00d6zkay, Y. Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Eur J Med Chem 2016;124:1026\u201340. https:\/\/doi.org\/10.1016\/j.ejmech.2016.10.042.","DOI":"10.1016\/j.ejmech.2016.10.042"},{"key":"2026030216130880215_j_znc-2025-0107_ref_032","doi-asserted-by":"crossref","unstructured":"Demir \u00d6zkay, \u00dc, Can, \u00d6D, Sa\u011fl\u0131k, BN, Acar \u00c7evik, U, Levent, S, \u00d6zkay, Y, et al.. Design, synthesis, and AChE inhibitory activity of new benzothiazole-piperazines. Bioorg Med Chem Lett 2016;26:5387\u201394. https:\/\/doi.org\/10.1016\/j.bmcl.2016.10.041.","DOI":"10.1016\/j.bmcl.2016.10.041"},{"key":"2026030216130880215_j_znc-2025-0107_ref_034","doi-asserted-by":"crossref","unstructured":"Binda, C, Wang, J, Pisani, L, Caccia, C, Carotti, A, Salvati, P, et al.. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J\u00a0Med Chem 2007;50:5848\u201352. https:\/\/doi.org\/10.1021\/jm070677y.","DOI":"10.1021\/jm070677y"},{"key":"2026030216130880215_j_znc-2025-0107_ref_035","unstructured":"Impact S. LLC, New York, NY, 2016; Prime. New York, NY: Schr\u00f6dinger, LLC; 2020."},{"key":"2026030216130880215_j_znc-2025-0107_ref_036","unstructured":"Schr\u00f6dinger Release 2020-3, Maestro, New York, NY: Schr\u00f6dinger, LLC; 2020."},{"key":"2026030216130880215_j_znc-2025-0107_ref_037","unstructured":"pkCSM. Available from: https:\/\/biosig.lab.uq.edu.au\/pkcsm\/prediction_single\/adme_1714859011.35"},{"key":"2026030216130880215_j_znc-2025-0107_ref_038","doi-asserted-by":"crossref","unstructured":"Daina, A, Michielin, O, Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717. https:\/\/doi.org\/10.1038\/srep42717.","DOI":"10.1038\/srep42717"},{"key":"2026030216130880215_j_znc-2025-0107_ref_039","unstructured":"Bank, RPD. RCSB PDB - 2V5Z: structure of human MAO B in complex with the selective inhibitor safinamide [Internet]. Available from: https:\/\/www.rcsb.org\/structure\/2V5Z [cited 18 Mar 2024]."},{"key":"2026030216130880215_j_znc-2025-0107_ref_040","unstructured":"Bank, RPD. RCSB PDB - 2V5Z: structure of human MAO B in complex with the selective inhibitor safinamide [Internet]. Available from: https:\/\/www.rcsb.org\/structure\/2V5Z [cited 30 Mar 2024]."},{"key":"2026030216130880215_j_znc-2025-0107_ref_041","doi-asserted-by":"crossref","unstructured":"Mikitsh, JL, Chacko, AM. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect Med Chem 2014;6:11\u201324. https:\/\/doi.org\/10.4137\/pmc.s13384.","DOI":"10.4137\/PMC.S13384"},{"key":"2026030216130880215_j_znc-2025-0107_ref_042","doi-asserted-by":"crossref","unstructured":"Daina, A, Zoete, V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016;11:1117\u201321. https:\/\/doi.org\/10.1002\/cmdc.201600182.","DOI":"10.1002\/cmdc.201600182"}],"container-title":["Zeitschrift f\u00fcr Naturforschung C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2025-0107\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2025-0107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:19:00Z","timestamp":1772468340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2025-0107\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":41,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2025,8,15]]},"published-print":{"date-parts":[[2026,3,26]]}},"alternative-id":["10.1515\/znc-2025-0107"],"URL":"https:\/\/doi.org\/10.1515\/znc-2025-0107","relation":{},"ISSN":["0939-5075","1865-7125"],"issn-type":[{"value":"0939-5075","type":"print"},{"value":"1865-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}